TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Unmethylated cystine-guanosine dinucleotide (CpG) motifs are pathogen-associated molecular patterns (PAMPs) associated with bacterial and viral-derived DNA that activate the innate and humoral immunity via toll-like receptor 9. This is a randomized controlled pilot study evaluating the clinical and immune correlates of a seroprotective immune response against a CpG-adjuvanted vaccine for hepatitis B.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland, Baltimore

Criteria

Inclusion Criteria:

In order to participate in this study, an individual must meet all the following criteria:

1. >18 years old

2. Diagnosed with CHB infection, without HIV, hepatitis C nor hepatitis D co-infections

3. Currently receiving OAV with HBV VL <100 IU/ml for ≥ 12 months

4. Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures.

5. Determined by medical history, targeted physical examination, and clinical judgement of the investigator to be in good health.

CHB infection is defined as any individual with documentation of the following in the past:

• Positive HBsAg and/or detectable HBV DNA test

Exclusion Criteria:

A participant will be ineligible to participate on this study if any of the following criteria are met:

1. Pregnancy or breast feeding.

2. Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to Day 1.

3. Received or plans to receive live virus vaccines within 4 weeks, and inactivated vaccine within 2 weeks prior to randomization; or plans to receive a non-study vaccine within 28 days after any dose of study vaccine (with exception for seasonal influenza vaccine within 14 days of study vaccine).

4. Administration of any blood products within 3 months prior to randomization.

5. Participation in a study with an investigational study product or device within 30 days of randomization.

6. Has allergies to any hepatitis B and/or yeast-based vaccines.

7. Subjects meeting any of the following laboratory parameters at screening:

1. ALT greater than 3 times the upper limit of normal

2. Elevated total bilirubin WITH direct bilirubin greater than 2 times upper limit of normal

8. Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as ≥ 38.0°C/100.4°F). Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.

9. Have any chronic or acute or unstable conditions that the investigator considers a contraindication to study participation.